Publications by authors named "Christopher Brawley"

Claim this Profile
T
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.
Emily Grist, Peter Dutey-Magni, Marina A Parry, Larissa Mendes, Ashwin Sachdeva, Christopher Brawley

Cell· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Marina A Parry, Emily Grist, Larissa Mendes, Peter Dutey-Magni, Ashwin Sachdeva, Christopher Brawley

Res Sq· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
Emily Grist, Stefanie Friedrich, Christopher Brawley, Larissa Mendes, Marina Parry

Genome Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Nicholas D James, Noel W Clarke, Adrian Cook, Adnan Ali, Alex P Hoyle, Christopher D Brawley

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Christopher D Brawley

JNCI Cancer Spectr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, Christopher D Brawley, Fiona C Ingleby

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Chris C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Adnan Ali

PLoS Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Hannah L Rush, Laura Murphy, Alicia K Morgans, Noel W Clarke, Adrian D Cook, Christopher D Brawley

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Adnan Ali, Alex Hoyle, Áine M Haran, Christopher D Brawley, Adrian Cook

JAMA Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
Clare Gilson, Fiona Ingleby, Duncan C Gilbert, Marina A Parry, Nafisah B Atako, Christopher Brawley

JCO Precis Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Claire L Vale, David Fisher, Andrew Kneebone, Christopher Parker, Maria Pearse, Christopher Brawley

Lancet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Adnan Ali, Alex P Hoyle, Christopher C Parker, Christopher D Brawley, Adrian Cook

Eur Urol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Alex P Hoyle, Adnan Ali, Nicholas D James, Adrian Cook, Christopher C Parker, Christopher D Brawley

Eur Urol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy for metastatic prostate cancer-Authors' reply.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Mahesh K B Parmar

Lancet· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle

Lancet· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis